Correction to: Clinical risk factors of stroke and major bleeding in patients with non-valvular atrial fibrillation under rivaroxaban: the EXPAND Study sub-analysis

Correction to: Heart and Vessels 10.1007/s00380-019-01425-x

In the original publication of the article, the Figure 2b and the Tables 2 and 3 were published incorrectly.

The corrected Figure 2b and Tables 2 and 3 are provided below.

Table 2.

Incidence rate and univariate analysis by Cox proportional hazards analysis of stroke/systemic embolism

	No. of event (%/year)	HR	95% CI	p value
Overall	176 (1.0)
Sex
Male	115 (1.0)	Reference		0.5283
Female	61 (1.1)	1.1	0.8, 1.5
Age class 1 (years-old)
< 65	23 (0.7)	Reference		0.0176
≥ 65	153 (1.1)	1.7	1.1, 2.6
Age class 2 (years-old)
< 65	23 (0.7)	Reference		0.0022
65–74	60 (0.9)	1.3	0.8, 2.2
≥ 75	93 (1.3)	2.0	1.3, 3.2
Body weight (kg)
≥ 60	84 (0.8)	Reference		0.0250
50–59	50 (1.1)	1.3	0.9, 1.9
< 50	33 (1.4)	1.7	1.1, 2.6
Systolic blood pressure (mmHg)
< 160	156 (1.0)	Reference		0.0928
≥ 160	12 (1.6)	1.6	0.9, 3.0
CrCl (mL/min)
≥ 50	112 (0.9)	Reference		0.0026
30–49	49 (1.5)	1.8	1.3, 2.5
< 30	3 (1.0)	1.2	0.4, 3.7
Comorbiditya
Congestive heart failure
–	129 (1.0)	Reference		0.8550
+	47 (1.0)	1.0	0.7, 1.4
Hypertension
–	44 (0.9)	Reference		0.2768
+	132 (1.1)	1.2	0.9, 1.7
Angina pectoris
–	157 (1.0)	Reference		0.7193
+	19 (0.9)	0.9	0.6, 1.5
Diabetes mellitus
–	121 (0.9)	Reference		0.0227
+	55 (1.3)	1.4	1.1, 2.0
Aortic aneurysm
–	174 (1.0)	Reference		0.7916
+	2 (0.8)	0.8	0.2, 3.3
Deep vein thrombosis
–	175 (1.0)	Reference		0.9718
+	1 (1.0)	1.0	0.2, 7.4
Pulmonary embolism
–	175 (1.0)	Reference		0.4012
+	1 (2.2)	2.3	0.3, 16.2
Dyslipidemia
–	105 (1.0)	Reference		0.6278
+	71 (1.0)	0.9	0.7, 1.3
Liver dysfunction
–	167 (1.0)	Reference		0.6999
+	9 (0.9)	0.9	0.5, 1.7
Renal dysfunction
–	176 (1.0)	Reference		0.6995
+	0 (0.0)	< 0.001	< 0.001
Medical historya
Stroke (ischemic/hemorrhagic)
–	91 (0.7)	Reference		< 0.0001
+	85 (2.3)	3.6	2.7, 4.8
Transient ischemic attack
–	169 (0.9)	Reference		0.4721
+	7 (1.3)	1.3	0.6, 2.8
Systemic embolism
–	174 (1.0)	Reference		0.6643
+	2 (1.4)	1.4	0.3, 5.5
Vascular disease (MI/PAD)
–	158 (1.0)	Reference		0.0352
+	18 (1.6)	1.7	1.0, 2.7
Malignant tumor
–	159 (1.0)	Reference		0.7657
+	17 (1.1)	1.1	0.7, 1.8
Bleeding/disposition of bleeding
–	169 (1.0)	Reference		0.9900
+	7 (1.0)	1.0	0.5, 2.1
Rivaroxaban dosage
15 mg/day	87 (0.9)	Reference		0.0658
10 mg/day	89 (1.2)	1.3	1.0, 1.8
Amount of drinking (unit/week)
No	105 (1.1)	Reference		0.1202
< 8	47 (0.8)	0.7	0.5, 1.0
≥ 8	24 (1.0)	0.9	0.6, 1.4
History of smoking
No	99 (0.9)	Reference		0.2940
In the past	54 (1.1)	1.1	0.8, 1.6
Current	23 (1.3)	1.4	0.9, 2.2
Type of AF
PAF	67 (0.9)	Reference		0.0799
Non-PAFb	109 (1.1)	1.3	1.0, 1.8
Using concomitant anti-plateletsa
–	138 (0.9)	Reference		0.0046
+	38 (1.5)	1.7	1.2, 2.4
Using concomitant NSAIDsa
–	172 (1.0)	Reference		0.9525
+	4 (1.0)	1.0	0.4, 2.8
CHADS2 score
< 3	76 (0.7)	Reference		< 0.0001
≥ 3	100 (1.7)	2.7	2.0, 3.6
CHA2DS2-VASc score
< 4	58 (0.6)	Reference		< 0.0001
≥ 4	118 (1.5)	2.5	1.9, 3.5
HAS-BLED score
< 2	60 (0.6)	Reference		< 0.0001
≥ 2	106 (1.7)	2.8	2.0, 3.8

HR hazard ratio, CI confidence interval, CrCl creatinine clearance, MI myocardial infraction, PAD peripheral arterial disease, AF atrial fibrillation, PAF paroxysmal atrial fibrillation, NSAIDs non-steroidal anti- inflammatory drugs

^aReference; without factor

^bPersistent and permanent atrial fibrillation

Table 3.

Incidence rate and univariate analysis by Cox proportional hazards analysis of ISTH major bleeding

	ISTH major bleeding
	No. of event (%/year)	HR	95% CI	p value
Overall	215 (1.2)
Sex
Male	147 (1.2)	Reference		0.8223
Female	68 (1.2)	1.0	0.7, 1.3
Age class 1 (years-old)
< 65	26 (0.7)	Reference		0.0027
≥ 65	189 (1.4)	1.9	1.2, 2.8
Age class 2 (years-old)
< 65	26 (0.7)	Reference		< 0.0001
65–74	66 (1.0)	1.3	0.8, 2.1
≥ 75	123 (1.7)	2.4	1.6, 3.6
Body weight (kg)
≥ 60	125 (1.3)	Reference		0.7249
50–59	52 (1.1)	0.9	0.7, 1.3
< 50	31 (1.3)	1.1	0.7, 1.6
Systolic blood pressure (mmHg)
< 160	199 (1.3)	Reference		0.2772
≥ 160	6 (0.8)	0.6	0.3, 1.4
CrCl (mL/min)
≥ 50	138 (1.1)	Reference		< 0.0001
30–49	59 (1.8)	1.8	1.3, 2.4
< 30	9 (2.9)	2.9	1.5, 5.6
Comorbiditya
CHF
–	149 (1.2)	Reference		0.1140
+	66 (1.4)	1.3	1.0, 1.7
Hypertension
–	53 (1.1)	Reference		0.1770
+	162 (1.3)	1.2	0.9, 1.7
Angina pectoris
–	181 (1.2)	Reference		0.0543
+	34 (1.7)	1.4	0.9, 2.1
Diabetes mellitus
–	159 (1.2)	Reference		0.4925
+	56 (1.3)	1.1	0.8, 1.5
Aortic aneurysm
–	210 (1.2)	Reference		0.2144
+	5 (2.1)	1.7	0.7, 4.2
DVT
–	212 (1.2)	Reference		0.0823
+	3 (3.1)	2.6	0.9, 8.3
PE
–	214 (1.2)	Reference		0.5833
+	1 (2.2)	1.7	0.2, 12.3
Dyslipidemia
–	125 (1.2)	Reference		0.9155
+	90 (1.2)	1.0	0.8, 1.3
Liver dysfunction
–	195 (1.2)	Reference		0.0252
+	20 (2.0)	1.7	1.1, 2.7
Renal dysfunction
–	215 (1.2)	Reference		0.6682
+	0 (0.0)	< 0.001	< 0.001, > 999.9
Medical history
Stroke (ischemic/hemorrhagic)
–	154 (1.1)	Reference		0.0065
+	61 (1.7)	1.5	1.1, 2.0
Transient ischemic attack
–	208 (1.2)	Reference		0.8415
+	7 (1.3)	1.1	0.5, 2.3
Systemic embolism
–	215 (1.2)	Reference		0.1736
+	0 (0.0)	< 0.001	< 0.001, > 999.9
Vascular disease (MI/PAD)
–	196 (1.2)	Reference		0.1345
+	19 (1.7)	1.4	0.9, 2.3
Malignant tumor
–	189 (1.2)	Reference		0.1145
+	26 (1.7)	1.4	0.9, 2.1
Bleeding/disposition of bleeding
–	200 (1.2)	Reference		0.0240
+	15 (2.1)	1.8	1.1, 3.1
Rivaroxaban dosage
15 mg/day	108 (1.1)	Reference		0.0635
10 mg/day	107 (1.4)	1.3	1.0, 1.7
Amount of drinking (unit/week)
No	128 (1.4)	Reference		0.0649
< 8	57 (1.0)	0.7	0.5, 1.0
≥ 8	30 (1.3)	0.9	0.6, 1.4
History of smoking
No	126 (1.2)	Reference		0.4144
In the past	71 (1.4)	1.2	0.9, 1.6
Current	18 (1.0)	0.9	0.5, 1.4
Type of AF
PAF	89 (1.1)	Reference		0.3453
Non-PAFb	126 (1.3)	1.1	0.9, 1.5
Using concomitant anti-plateletsa
–	166 (1.1)	Reference		0.0003
+	49 (2.0)	1.8	1.3, 2.5
Using concomitant NSAIDsa
–	211 (1.2)	Reference		0.7265
+	4 (1.0)	0.8	0.3, 2.3
CHADS2 score
< 3	121 (1.0)	Reference		0.0009
≥ 3	94 (1.6)	1.6	1.2, 2.1
CHA2DS2-VASc score
< 4	92 (1.0)	Reference		0.0001
≥ 4	123 (1.6)	1.7	1.3, 2.2
HAS-BLED score
< 2	92 (0.9)	Reference		< 0.0001
≥ 2	111 (1.7)	1.9	1.4, 2.5

HR hazard ratio, CI confidence interval, ISTH International Society on Thrombosis and Haemostasis, CrCl creatinine clearance, MI myocardial infraction, PAD peripheral arterial disease, AF atrial fibrillation, PAF paroxysmal atrial fibrillation, NSAIDs non-steroidal anti-inflammatory drugs

^aReference; without factor

^bPersistent and permanent atrial fibrillation